Recent genetic analyses have shown an unsuspected role for autophagy in Crohn's disease (CD)1, revealing a coding polymorphism in the autophagy gene ATG16L1 that is associated with increased risk of CD4. However, the biological function of ATG16L1 remains relatively unexplored, and the mechanism whereby the T300A risk polymorphism predisposes to CD is not known. The experiments proposed in this application will yield novel insights into the biology of ATG16L1 T300A and provide clues to novel means to preventing or treating CD. Our overarching hypothesis is that ATG16L1 is required for autophagy and that the ATG16L1 T300A CD risk polymorphism contributes to disease by regulating cell-specific defense responses that are central to maintaining intestinal mucosal homeostasis. To test this hypothesis, we propose to determine the functional effects of ATG16L1 T300A in the cellular response to stress and pro-inflammatory ligands and to examine the effects of autophagy mutations in secretion programs essential for mast cell function and Paneth cell function. Furthermore, we will investigate the molecular determinants that contribute to T300A-associated phenotypes and present a novel approach for analysis of gene regulatory networks that will offer insight into the function of ATG16L1 T300A in CD. To investigate these questions, we will employ several genetic approaches, using two unique mouse models developed in the lab (Atg16l1 T300A knock-in mice and conditional deletion of Atg16l1) as well as primary peripheral blood cells from healthy individuals and CD patients bearing this polymorphism. The preliminary data described demonstrate the feasibility of the specific aims of this proposal. The ultimate aim of these studies is to understand the detailed molecular mechanism of ATG16L1 activation that gives rise to aberrant immunological responses to patients with CD. Answers to this central question will have direct clinical implications.
Aim 1) Use perturbational profiling by microbial factors to determine how ATG16L1 T300A is involved in CD susceptibility in the context of interactions with the environment (microbes).
Aim 2) Unravel underlying mechanisms of phenotypes associated with ATG16L1 T300A in non-canonical autophagy pathways that involve secretion.
Aim 3) Identify the molecular determinants of ATG16L1 T300A that contribute to disease risk in CD patients.
Aim 4) Identify ATG16L1 T300A-specific regulatory network modules to gain insights into autophagy- associated phenotypes involved in CD pathogenesis.

Public Health Relevance

Recent studies have identified that an autophagy gene (ATG16L1 T300A) increases the risk of developing Crohn's disease (CD), a condition that affects more than a million people in the United States and is currently incurable by medical or surgical interventions;however, the reason why this risk factor increases susceptibility to CD is unknown. This proposal represents the first known effort to investigate the mechanisms whereby ATG16L1 T300A leads to increased susceptibility to CD using both human cells and a novel mouse model that mimics the clinical findings seen in patients with the disease. There is high potential that this work will derive novel therapeutic targets for CD, and we believe that the approach outlined in this application will form the basis for functional analysis to other genetic risk/protective factors associated with complex immune disorders.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK097485-02
Application #
8588317
Study Section
Gastrointestinal Mucosal Pathobiology Study Section (GMPB)
Program Officer
Grey, Michael J
Project Start
2013-01-01
Project End
2016-12-31
Budget Start
2014-01-01
Budget End
2014-12-31
Support Year
2
Fiscal Year
2014
Total Cost
$426,846
Indirect Cost
$171,542
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
VanDussen, Kelli L; Liu, Ta-Chiang; Li, Dalin et al. (2014) Genetic variants synthesize to produce paneth cell phenotypes that define subtypes of Crohn's disease. Gastroenterology 146:200-9
Lassen, Kara G; Kuballa, Petric; Conway, Kara L et al. (2014) Atg16L1 T300A variant decreases selective autophagy resulting in altered cytokine signaling and decreased antibacterial defense. Proc Natl Acad Sci U S A 111:7741-6
Lassen, Kara G; Xavier, Ramnik J (2014) An alteration in ATG16L1 stability in Crohn disease. Autophagy 10:1858-60
Cheng, Shih-Chin; Quintin, Jessica; Cramer, Robert A et al. (2014) mTOR- and HIF-1?-mediated aerobic glycolysis as metabolic basis for trained immunity. Science 345:1250684
Conway, Kara L; Kuballa, Petric; Song, Joo-Hye et al. (2013) Atg16l1 is required for autophagy in intestinal epithelial cells and protection of mice from Salmonella infection. Gastroenterology 145:1347-57
Begun, Jakob; Xavier, Ramnik J (2013) Autophagy at the crossroads of metabolism and cellular defense. Curr Opin Gastroenterol 29:588-96
Shaw, Stanley Y; Tran, Khoa; Castoreno, Adam B et al. (2013) Selective modulation of autophagy, innate immunity, and adaptive immunity by small molecules. ACS Chem Biol 8:2724-33
Knights, Dan; Lassen, Kara G; Xavier, Ramnik J (2013) Advances in inflammatory bowel disease pathogenesis: linking host genetics and the microbiome. Gut 62:1505-10